Search Results - "ORENS, J"

Characterization of Respiratory Pathogens in Contemporary Lung Transplant Recipients by Bazemore, K., Permpalung, N., Rohly, M., Timofte, I., Brown, A., Orens, J., Iacono, A., Nathan, S., Avery, R., Valentine, H., Agbor-Enoh, S., Shah, P.

“…This study assessed respiratory pathogens isolated in the first year post lung transplant in a recent multicenter cohort. Prior studies may not reflect current…”
Get full text

Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation by Shah, R. J., Diamond, J. M., Cantu, E., Flesch, J., Lee, J. C., Lederer, D. J., Lama, V. N., Orens, J., Weinacker, A., Wilkes, D. S., Roe, D., Bhorade, S., Wille, K. M., Ware, L. B., Palmer, S. M., Crespo, M., Demissie, E., Sonnet, J., Shah, A., Kawut, S. M., Bellamy, S. L., Localio, A. R., Christie, J. D.

“…Primary graft dysfunction (PGD) is a major cause of early mortality after lung transplant. We aimed to define objective estimates of PGD risk based on readily…”
Get full text

National Healthcare Delivery Systems Influence Lung Transplant Outcomes for Cystic Fibrosis by Merlo, C. A., Clark, S. C., Arnaoutakis, G. J., Yonan, N., Thomas, D., Simon, A., Thompson, R., Thomas, H., Orens, J., Shah, A. S.

“…Successful lung transplantation (LTx) depends on multiple components of healthcare delivery and performance. Therefore, we conducted an international registry…”
Get full text

The Effect of the Cystic Fibrosis Care Center on Lung Transplant Outcomes by Krishnan, A., Bush, E.L., Chidi, A., Nolley, E., Agbor-Enoh, S., West, N.E., Tallarico, E., Orens, J.B., Ha, J., Shah, P., Segev, D., Massie, A., Higgins, R.S., Merlo, C.A.

“…Since 1961 the Cystic Fibrosis Foundation has designated certain institutions devoted to treating cystic fibrosis (CF) as Cystic Fibrosis Care Centers (CFCC)…”
Get full text

Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness by Studer, S.M, Levy, R.D, McNeil, K, Orens, J.B

“…The success of lung transplantation has improved over time as evidenced by better long-term survival and functional outcomes. Despite the success of this…”
Get full text

High‐Quality CMV‐Specific CD4+ Memory Is Enriched in the Lung Allograft and Is Associated With Mucosal Viral Control by Akulian, J. A., Pipeling, M. R., John, E. R., Orens, J. B., Lechtzin, N., McDyer, J. F.

“…The maintenance of CMV‐specific T cell memory in lung transplant recipients (LTRs) is critical for host defense and allograft durability, particularly in…”
Get full text

Simulated Regionalization of Heart and Lung Transplantation in the United States by Magruder, J. T., Shah, A. S., Crawford, T. C., Grimm, J. C., Kim, B., Orens, J. B., Bush, E. L., Higgins, R. S., Merlo, C. A.

“…We simulated the impact of regionalization of isolated heart and lung transplantation within United Network for Organ Sharing (UNOS) regions. Overall, 12 594…”
Get full text

Splenic Irradiation for the Treatment of Severe Antibody‐Mediated Rejection by Orandi, B. J., Lonze, B. E., Jackson, A., Terezakis, S., Kraus, E. S., Alachkar, N., Bagnasco, S. M., Segev, D. L., Orens, J. B., Montgomery, R. A.

“…Patients requiring desensitization prior to renal transplantation are at risk for developing severe antibody‐mediated rejection (AMR) refractory to treatment…”
Get full text

Allograft Injury and Outcomes in African American Lung Transplant Recipients by Agbor-Enoh, S., Charya, A., Jang, M., Luikart, H., Shah, P., Matthews, J., Brown, A.W., Timofte, I., Fideli, U., Kong, H., Bhatti, K., Marishta, A., Yang, Y., Tunc, I., Berry, G., Marboe, C., Iacono, A., Nathan, S., Khush, K., Orens, J.B., Valantine, H.

“…African American patients (AA) have poorer outcomes than White patients (W) after heart and kidney transplant. Little is known about differential outcomes in…”
Get full text

Clinical Outcomes after Pediatric Lung Transplantation at Cystic Fibrosis Care Centers by Chidi, A.P., Krishnan, A., Nolley, E., Agbor-Enoh, S., West, N.E., Tallarico, E., Thaxton, A., Orens, J.B., Ha, J., Shah, P.D., Segev, D., Massie, A., Higgins, R.S., Merlo, C.A., Bush, E.L.

“…Clinical outcomes remain extremely poor for children with cystic fibrosis undergoing lung transplantation. Since 1961, the Cystic Fibrosis Foundation has…”
Get full text

Donor-Derived-Cell-Free DNA to Identify Primary Graft Dysfunction Patients at Risk of Chronic Lung Allograft Dysfunction by Keller, M.B., Shah, P., Bush, E., Diamond, J.M., Matthews, J., Brown, A.W., Timofte, I., Fideli, U.S., Kong, H., Marishta, A., Bhatti, K., Yang, Y., Tunc, I., Luikart, H., Berry, G., Marboe, C., Iacono, A., Nathan, S., Khush, K.K., Orens, J., Jang, M., Valentine, H.A., Agbor-Enoh, S.

“…Primary Graft Dysfunction (PGD) is a risk factor for Chronic Lung Allograft Dysfunction (CLAD). However, this association requires further examination for…”
Get full text

Improved Survival after Repeat Lung Transplantation at Cystic Fibrosis Care Centers by Chidi, A.P., Krishnan, A., Nolley, E., Agbor-Enoh, S., West, N.E., Tallarico, E., Thaxton, A., Orens, J.B., Ha, J.S., Shah, P.D., Segev, D., Massie, A., Higgins, R.S., Merlo, C.A., Bush, E.L.

“…Patients who undergo repeat lung transplantation (LT) are at high risk for perioperative complications. The complexity of their care requires specialized…”
Get full text

Lung Transplantation: DSA to AMR Trajectory by Ponor, I., Levine, D., Cochrane, A., Philogene, M.C., Shah, P.D., Mathew, J., Brown, A.W., Timofte, I., Fideli, U., Kong, H., Marishta, A., Yang, Y., Tunc, I., Luikart, H., Berry, G., Marboe, C., Iacono, A., Nathan, S., Khush, K.K., Orens, J., Jang, M., Valentine, H., Agbor-Enoh, S.

“…Donor specific antibodies(DSA) are a major risk factor for antibody mediated rejection (AMR) and allograft failure in lung transplant recipients (LTs). The…”
Get full text

To Treat or Not to Treat: DSA Positive Lung Transplant Recipients by Agbor-Enoh, S., Ponor, I., Shah, P., Levine, D., Cochrane, A., Philogene, M., Matthews, J., Brown, A.W., Timofte, I., Fideli, U., Kong, H., Marishta, A., Bhatti, K., Tunc, I., Yang, Y., Luikart, H., Marboe, C., Berry, G., Iacono, A., Nathan, S., Khush, K.K., Orens, J., Jang, M., Valantine, H.

“…Donor-specific antibodies (DSA) is a major risk factor for chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx). Unfortunately, DSA…”
Get full text

Lung Transplant Recipients with Severe Primary Graft Dysfunction Requiring ECMO Had Similar Donor-Derived Cell-Free DNA Levels and Lung Function as Matched Controls by Timofte, I., Iacono, A., Terrin, M., Vesselinov, R., Bhatti, K., Marishta, A., Young, C., Pervaiz, A., Fideli, U., Tunc, I., Kwesiga, D.M., Orens, J., Shah, P., Nathan, S.D., Brown, A.W., Valantine, H.A., Agbor-Enoh, S.

“…Extracorporeal Membrane Oxygenation (ECMO) is a lifesaving procedure in lung transplant recipients with severe primary graft dysfunction (PGD). There is…”
Get full text

Implications of ECMO Bridging and Salvage Strategies on Mortality and PGD by Cantu, E., Bermudez, C., Cevasco, M., Suzuki, Y., Buckley, T., Galati, V., Majeti, N., Benvenuto, L., Anderson, M., Wille, K.M., Weinacker, A., Dhillon, G., Orens, J., Shah, P., Lama, V., McDyer, J., Snyder, L., Palmer, S., Hartwig, M., Hage, C., Singer, J., Calfee, C., Kukreja, J., Greenland, J., Ware, L., Hsu, J., Gallop, R., Diamond, J., Christie, J.

“…ECMO is increasingly used for bridging and salvage therapies in lung transplantation, with favorable short-term results. Mid- to long-term outcomes of ECMO use…”
Get full text

Plasma Cytokines and Chemokines in Primary Graft Dysfunction Post‐Lung Transplantation by Hoffman, S. A., Wang, L., Shah, C. V., Ahya, V. N., Pochettino, A., Olthoff, K., Shaked, A., Wille, K., Lama, V. N., Milstone, A., Ware, L. B., Orens, J., Weinacker, A., Demissie, E., Bellamy, S., Kawut, S. M., Hancock, W. W., Christie, J. D.

“…Primary graft dysfunction (PGD) after lung transplantation causes significant morbidity and mortality. We aimed to determine the role of cytokines and…”
Get full text

Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post–Lung Transplant Primary Graft Dysfunction Risk by Cantu, E., Suzuki, Y., Diamond, J. M., Ellis, J., Tiwari, J., Beduhn, B., Nellen, J. R., Shah, R., Meyer, N. J., Lederer, D. J., Kawut, S. M., Palmer, S. M., Snyder, L. D., Hartwig, M. G., Lama, V. N., Bhorade, S., Crespo, M., Demissie, E., Wille, K., Orens, J., Shah, P. D., Weinacker, A., Weill, D., Wilkes, D., Roe, D., Ware, L. B., Wang, F., Feng, R., Christie, J. D.

“…The authors previously identified plasma plasminogen activator inhibitor‐1 (PAI‐1) level as a quantitative lung injury biomarker in primary graft dysfunction…”
Get full text

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension by YUAN, J. X.-J, ALDINGER, A. M, JUHASZOVA, M, JIAN WANG, CONTE, J. V, GAINE, S. P, ORENS, J. B, RUBIN, L. J

“…Primary pulmonary hypertension (PPH) is a rare disease of unknown cause. Although PPH and secondary pulmonary hypertension (SPH) share many clinical and…”
Get full text

Elevated Plasma Long Pentraxin‐3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis by Diamond, J. M., Lederer, D. J., Kawut, S. M., Lee, J., Ahya, V. N., Bellamy, S., Palmer, S. M., Lama, V. N., Bhorade, S., Crespo, M., Demissie, E., Sonett, J., Wille, K., Orens, J., Shah, P. D., Weinacker, A., Weill, D., Kohl, B. A., Deutschman, C. C., Arcasoy, S., Shah, A. S., Belperio, J. A., Wilkes, D., Reynolds, J. M., Ware, L. B., Christie, J. D.

“…Primary graft dysfunction (PGD) after lung transplantation may result from ischemia reperfusion injury (IRI). The innate immune response to IRI may be mediated…”
Get full text